Establishment Labs Holdings Inc. $ESTA Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. cut its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 8.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,994,298 shares of the company’s stock after selling 172,684 shares during the period. Brown Advisory Inc. owned approximately 0.07% of Establishment Labs worth $145,344,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs in the fourth quarter valued at about $47,000. Mudita Advisors LLP increased its holdings in shares of Establishment Labs by 1.9% in the fourth quarter. Mudita Advisors LLP now owns 699,703 shares of the company’s stock valued at $50,994,000 after purchasing an additional 12,939 shares during the period. Marshall Wace LLP increased its holdings in shares of Establishment Labs by 45.9% in the fourth quarter. Marshall Wace LLP now owns 198,374 shares of the company’s stock valued at $14,457,000 after purchasing an additional 62,362 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of Establishment Labs in the fourth quarter valued at about $758,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Establishment Labs by 52.2% in the fourth quarter. Wells Fargo & Company MN now owns 8,443 shares of the company’s stock worth $615,000 after buying an additional 2,896 shares during the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on ESTA. BTIG Research raised their target price on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen downgraded Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Wednesday, May 6th. Canaccord Genuity Group increased their price target on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Stephens increased their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $87.14.

Insider Buying and Selling at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the transaction, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 330,000 shares of company stock valued at $22,854,538 in the last quarter. Company insiders own 9.99% of the company’s stock.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $82.14 on Friday. The company has a market capitalization of $2.42 billion, a P/E ratio of -55.13 and a beta of 1.11. The business’s 50 day moving average is $68.81 and its two-hundred day moving average is $69.17. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. Establishment Labs Holdings Inc. has a 12-month low of $33.35 and a 12-month high of $86.00.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.70) EPS. Analysts expect that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.